Company Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.
The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.
It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.
In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer.
Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration.
The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
| Country | United States |
| Founded | 2010 |
| IPO Date | Mar 9, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Dr. Lan Huang Ph.D. |
Contact Details
Address: 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park, New Jersey 07932 United States | |
| Phone | 646-528-4184 |
| Website | beyondspringpharma.com |
Stock Details
| Ticker Symbol | BYSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001677940 |
| CUSIP Number | G10830100 |
| ISIN Number | KYG108301006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lan Huang Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Linqing Jia | Co-Founder |
| Dr. June Lu Ph.D. | Chief Scientific Officer |
| Stephen Kilmer | Head of Investor Relations |
| Gregg Russo | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 12, 2024 | EFFECT | Notice of Effectiveness |
| Jul 2, 2024 | F-3/A | Filing |
| Jun 12, 2024 | F-3 | Filing |
| Jun 12, 2024 | 6-K | Report of foreign issuer |
| Jun 12, 2024 | 424B5 | Filing |
| Apr 29, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 18, 2024 | 6-K | Report of foreign issuer |
| Feb 26, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | 6-K | Report of foreign issuer |